A broad analysis of resistance development in the malaria parasite

Nature Communications

Volumn 7, Issue , 2016, Pages

  Corey, Victoria C ^a   Lukens, Amanda K ^b,c   Istvan, Eva S ^d   Lee, Marcus C S ^e   Franco, Virginia ^f   Magistrado, Pamela ^b   Coburn Flynn, Olivia ^e   Sakata Kato, Tomoyo ^b   Fuchs, Olivia ^a   Gnädig, Nina F ^e   Goldgof, Greg ^a   Linares, Maria ^f   Gomez Lorenzo, Maria G ^f   De Cózar, Cristina ^f   Lafuente Monasterio, Maria Jose ^f   Prats, Sara ^f   Meister, Stephan ^a   Tanaseichuk, Olga ^g   Wree, Melanie ^a   Zhou, Yingyao ^g   Willis, Paul A ^h   Gamo, Francisco Javier ^f   Goldberg, Daniel E ^d   Fidock, David A ^e   Wirth, Dyann F ^b,c   Winzeler, Elizabeth A ^a   more..

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CPS ^*  (United States)

^f GLAXOSMITHKLINE   (Spain)

^g GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^h Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMINO ACID TRANSFER RNA LIGASE; ANTIMALARIAL AGENT; DIHYDROOROTATE DEHYDROGENASE; HEAT SHOCK PROTEIN 90; MICROORGANISM PROTEIN; PLASMODIUM FALCIPARUM ADENOSINE TRIPHOSPHATASE 4; PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANCE TRANSPORTER; PLASMODIUM FALCIPARUM CYCLIC AMINE RESISTANCE LOCUS; PLASMODIUM FALCIPARUM MULTI DRUG RESISTANCE TRANSPORTER 1; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG;

ALLELE; ANTIMALARIAL AGENT; CHEMOTHERAPY; CYTOCHROME; DRUG RESISTANCE; MALARIA; MICROBIAL ACTIVITY; PARASITE RESISTANCE; RNA;

ALLELE; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; IN VITRO SELECTION; NONHUMAN; PLASMODIUM FALCIPARUM; ANIMAL; CELL CLONE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; INDEL MUTATION; MUTATION; PARASITE; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTIMALARIALS; CLONE CELLS; DRUG RESISTANCE; INDEL MUTATION; MUTATION; PARASITES; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84975055690     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11901     Document Type: Article

References (42)

1. World Health Organization. World Malaria Report (WHO, Geneva, 2015).
2. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. The Lancet 386, 31-45 (2015).
3. Flannery, E. L., Chatterjee, A. K., Winzeler, E. A. Antimalarial drug discovery-approaches and progress towards new medicines. Nat. Rev. Microbiol. 11, 849-862 (2013).
4. Noedl, H. et al. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359, 2619-2620 (2008).
5. Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455-467 (2009).
6. Ashley, E. A. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411-423 (2014).
7. Winzeler, E. A., Manary, M. J. Drug resistance genomics of the antimalarial drug artemisinin. Genome Biol. 15, 544 (2014).
8. Saunders, D. L., Vanachayangkul, P., Lon, C. Dihydroartemisininpiperaquine failure in Cambodia. N. Engl. J. Med. 371, 484-485 (2014).
9. World Health Organization. Status report on artemisinin resistance. Global Malaria Programme (2014).
10. Spangenberg, T. et al. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS ONE 8, e62906 (2013).
11. Gamo, F.-J. et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305-310 (2010).
12. Guiguemde, W. A. et al. Chemical genetics of Plasmodium falciparum. Nature 465, 311-315 (2010).
13. Plouffe, David M. et al. High-throughput assay and discovery of small molecules that interrupt malaria transmission. Cell Host Microbe 19, 114-126 (2016).
14. Kuhen, K. L. et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, prevention of disease transmission. Antimicrob. Agents Chemother. 58, 5060-5067 (2014).
15. Bopp, S. E. R. et al.Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet. 9, e1003293 (2013).
16. Dong, C. K. et al. Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. Chem. Biol. 18, 1602-1610 (2011).
17. Lukens, A. K. et al. Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors. J. Infect. Dis. 211, 1097-1103 (2015).
18. Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180 (2010).
19. Flannery, E. L. et al. Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. ACS Chem. Biol. 10, 413-420 (2015).
20. Jimenez-Diaz, M. B. et al. (\+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc. Natl Acad. Sci. USA 111, E5455-E5462 (2014).
21. Martin, E. J. et al. Measuring diversity: experimental design of combinatorial libraries for drug discovery. J. Med. Chem. 38, 1431-1436 (1995).
22. Matter, H. Selecting optimally diverse compounds from structure databases:a validation study of two-dimensional and three-dimensional molecular descriptors. J. Med. Chem. 40, 1219-1229 (1997).
23. Walliker, D. et al. Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 236, 1661-1666 (1987).
24. Oduola, A. M., Weatherly, N. F., Bowdre, J. H., Desjardins, R. E. Plasmodium falciparum: cloning by single-erythrocyte micromanipulation and heterogeneity in vitro. Exp. Parasitol. 66, 86-95 (1988).
25. Wellems, T. E. et al. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 345, 253-255 (1990).
26. Ponnudurai, T., Leeuwenberg, A. D., Meuwissen, J. H. Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in vitro culture. Trop. Geogr. Med. 33, 50-54 (1981).
27. Campbell, C. C., Collins, W. E., Nguyen-Dinh, P., Barber, A., Broderson, J. R. Plasmodium falciparum gametocytes from culture in vitro develop to sporozoites that are infectious to primates. Science 217, 1048-1050 (1982).
28. Looareesuwan, S. et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54, 62-66 (1996).
29. Lukens, A. K. et al. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance. Proc. Natl Acad. Sci. USA 111, 799-804 (2014).
30. Ross, L. S. et al. In Vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth. J. Biol. Chem. 289, 17980-17995 (2014).
31. Herman, J. D. et al. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. Sci. Transl. Med. 7, 288ra77 (2015).
32. Plouffe, D. et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl Acad. Sci. USA 105, 9059-9064 (2008).
33. Linares, M. et al. Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay. Malar. J. 14, 441 (2015).
34. Sanz, L. M. et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS ONE 7, e30949 (2012).
35. Desjardins, R. E., Canfield, C. J., Haynes, J. D., Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16, 710-718 (1979).
36. Goodyer, I. D., Taraschi, T. F. Plasmodium falciparum: a simple, rapid method for detecting parasite clones in microtiter plates. Exp. Parasitol. 86, 158-160 (1997).
37. Manary, M. J. et al. Identification of pathogen genomic variants through an integrated pipeline. BMC Bioinformatics 15, 1-14 (2014).
38. QikProp. version 4.2 Schrödinger, LLC, New York, NY (2014).
39. Cruciani, G., Crivori, P., Carrupt, P. A., Testa, B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. THEOCHEM 503, 17-30 (2000).
40. Rogers, D., Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model 50, 742-754 (2010).
41. Wilkens, S. J., Janes, J., Su, A. I. HierS: hierarchical scaffold clustering using topological chemical graphs. J. Med. Chem. 48, 3182-3193 (2005).
42. Peng, H., Long, F., Ding, C. Feature selection based on mutual information: criteria of max-dependency, max-relevance, min-redundancy. IEEE Trans. Pattern Anal. Mach. Intell. 27, 1226-1238 (2005).